Dominique Lagadic-Gossmann
Overview
Explore the profile of Dominique Lagadic-Gossmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merret P, Sparfel L, Lavau C, Lagadic-Gossmann D, Martin-Chouly C
Biochimie
. 2024 Sep;
228:127-137.
PMID: 39307409
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is a chronic disease with increasing prevalence and for which non-invasive biomarkers are needed. Environmental endocrine disruptors (EDs) are known to be involved in...
2.
Amosse J, Souki R, El Hajjar M, Marques M, Genet V, Fevrier A, et al.
Ecotoxicol Environ Saf
. 2024 Sep;
285:117065.
PMID: 39305779
Exposure to polycyclic aromatic hydrocarbons (PAHs), ubiquitously environmental contaminant, leads to the development of major toxic effects on human health, such as carcinogenic and immunosuppressive alterations reported for the most...
3.
Voisin T, Joannes A, Morzadec C, Lagadic-Gossmann D, Le Naoures C, de Latour B, et al.
J Nutr Biochem
. 2024 Jan;
125:109558.
PMID: 38185349
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease. Up to now, no treatment can stop the progression of IPF. Vitamin D3 (VD) reduces experimental lung fibrosis...
4.
Bernal K, Touma C, Le-Grand B, Rose S, Degerli S, Genet V, et al.
Chemosphere
. 2023 Dec;
349:140883.
PMID: 38092172
The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. This disease encompasses several stages, from steatosis to steatohepatitis and, eventually, to fibrosis and cirrhosis. Exposure to environmental...
5.
Holme J, Vondracek J, Machala M, Lagadic-Gossmann D, Vogel C, Le Ferrec E, et al.
Biochem Pharmacol
. 2023 Sep;
216:115801.
PMID: 37696458
Air pollution is the leading cause of lung cancer after tobacco smoking, contributing to 20% of all lung cancer deaths. Increased risk associated with living near trafficked roads, occupational exposure...
6.
Souki R, Amosse J, Genet V, Le Gall M, Saintpierre B, Letourneur F, et al.
Environ Pollut
. 2023 Apr;
328:121653.
PMID: 37080521
Polycyclic aromatic hydrocarbons (PAHs) are widely distributed environmental contaminants, triggering deleterious effects such as carcinogenicity and immunosuppression, and peripheral blood mononuclear cells (PBMCs) are among the main cell types targeted...
7.
Le Mentec H, Monniez E, Legrand A, Monvoisin C, Lagadic-Gossmann D, Podechard N
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835354
Non-alcoholic fatty liver disease (NAFLD), which starts with liver steatosis, is a growing worldwide epidemic responsible for chronic liver diseases. Among its risk factors, exposure to environmental contaminants, such as...
8.
Bernal K, Touma C, Erradhouani C, Boronat-Belda T, Gaillard L, Al Kassir S, et al.
FEBS Lett
. 2022 Aug;
596(24):3107-3123.
PMID: 35957500
The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro...
9.
Kassotis C, Vom Saal F, Babin P, Lagadic-Gossmann D, Le Mentec H, Blumberg B, et al.
Biochem Pharmacol
. 2022 Jun;
202:115145.
PMID: 35716579
No abstract available.
10.
Heindel J, Howard S, Agay-Shay K, Arrebola J, Audouze K, Babin P, et al.
Biochem Pharmacol
. 2022 Jun;
202:115144.
PMID: 35714447
No abstract available.